Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.
Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 11, 15, 3, 35 and 10 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 11 and 3 molecules, respectively.
Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Drug Addiction - Overview
Drug Addiction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Drug Addiction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Addiction - Companies Involved in Therapeutics Development
Adjuvance Technologies Inc
Aelis Farma SAS
Aether Therapeutics Inc
Allaysis LLC
Amygdala Neurosciences Inc
Ananda Scientific Inc
Aphios Corp
Assertio Holdings Inc
Astraea Therapeutics LLC
Better Life Pharmaceuticals Inc
BioCorRx Inc
Camino Pharma LLC
Cerevel Therapeutics Holdings Inc
Charleston Laboratories Inc
Chiesi Farmaceutici SpA
Chiromics LLC
Clear Scientific LLC
Consegna Pharma Inc
Curemark LLC
D&A Pharma SAS
Daya Drug Discoveries Inc
DD Therapeutics LLC
Delix Therapeutics Inc
Denovo Biopharma LLC
Elysium Therapeutics Inc
Embera NeuroTherapeutics Inc
EncepHeal Therapeutics Inc
Ensysce Biosciences Inc
Entheon Biomedical Corp
EryDel SpA
F. Hoffmann-La Roche Ltd
Foresee Pharmaceuticals Co Ltd
Hua Medicine Shanghai Ltd
IMV Inc
InterveXion Therapeutics LLC
Intra-Cellular Therapies Inc
Jazz Pharmaceuticals Plc
Kdac Therapeutics Inc
KemPharm Inc
Kinoxis Therapeutics Pty Ltd
Kyorin Pharmaceutical Co Ltd
MAKScientific LLC
MElkin Pharmaceuticals
Mind Medicine MindMed Inc
Mydecine Innovations Group Inc
Myosin Therapeutics Inc
Naprogenix Inc
NFL Biosciences SAS
Novartis AG
Omeros Corp
Ovid Therapeutics Inc
P2D Inc
PAION AG
Proniras Corp
Protagenic Therapeutics Inc
Qingdao Primedicine Pharmaceutical Technology Co Ltd
Relmada Therapeutics Inc
Revive Therapeutics Ltd
Saniona AB
Sen-Jam Pharmaceutical LLC
Tonix Pharmaceuticals Holding Corp
Trevena Inc
Tris Pharma Inc
Vallon Pharmaceuticals Inc
Vivozon Inc
Zelira Therapeutics Ltd
Drug Addiction - Drug Profiles
(hydrocodone bitartrate + naltrexone hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(metyrapone + oxazepam) - Drug Profile
Product Description
Mechanism Of Action
History of Events
6-BN - Drug Profile
Product Description
Mechanism Of Action
History of Events
AEF-0117 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AM-4113 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AM-4302 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ANS-6637 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AT-1001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AT-121 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AT-200 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AT-312 - Drug Profile
Product Description
Mechanism Of Action
baclofen - Drug Profile
Product Description
Mechanism Of Action
BETR-002 - Drug Profile
Product Description
Mechanism Of Action
BICX-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Biologic to Agonize TLR4 for Drug Addiction - Drug Profile
Product Description
Mechanism Of Action
buprenorphine - Drug Profile
Product Description
Mechanism Of Action
History of Events
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
History of Events
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
History of Events
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
History of Events
CC-318 - Drug Profile
Product Description
Mechanism Of Action
cebranopadol - Drug Profile
Product Description
Mechanism Of Action
History of Events
CHF-6563 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CM-1212 - Drug Profile
Product Description
Mechanism Of Action
CS-1103 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CVL-354 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CVL-936 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CYD-179 - Drug Profile
Product Description
Mechanism Of Action
DDD-024 - Drug Profile
Product Description
Mechanism Of Action
dimethyltryptamine - Drug Profile
Product Description
Mechanism Of Action
DLX-7 - Drug Profile
Product Description
Mechanism Of Action
dronabinol - Drug Profile
Product Description
Mechanism Of Action
History of Events
Ery-CoCe - Drug Profile
Product Description
Mechanism Of Action
esmethadone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
FP-004 - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Methamphetamine Abuse - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate Cocaine Hydrolase for Cocaine Abuse and Addiction - Drug Profile
Product Description
Mechanism Of Action
History of Events
h-2E2 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ibudilast - Drug Profile
Product Description
Mechanism Of Action
History of Events
ITI-333 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IXTM-200 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IXTm-250 - Drug Profile
Product Description
Mechanism Of Action
IXTV-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
JDTic - Drug Profile
Product Description
Mechanism Of Action
JJC-8091 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KDAC-0001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KNX-100 - Drug Profile
Product Description
Mechanism Of Action
KNX-300 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KNX-400 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KP-879 - Drug Profile
Product Description
Mechanism Of Action
mavoglurant - Drug Profile
Product Description
Mechanism Of Action
History of Events
MC-100093 - Drug Profile
Product Description
Mechanism Of Action
MP-1104 - Drug Profile
Product Description
Mechanism Of Action
MT-110 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MYCO-004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
naloxone - Drug Profile
Product Description
Mechanism Of Action
History of Events
NFL-201 - Drug Profile
Product Description
Mechanism Of Action
NS-2359 - Drug Profile
Product Description
Mechanism Of Action
History of Events
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
History of Events
OV-329 - Drug Profile
Product Description
Mechanism Of Action
History of Events
oxycodone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
oxytocin - Drug Profile
Product Description
Mechanism Of Action
History of Events
PMS-001 - Drug Profile
Product Description
Mechanism Of Action
pomaglumetad methionil - Drug Profile
Product Description
Mechanism Of Action
History of Events
psilocybin - Drug Profile
Product Description
Mechanism Of Action
PT-00114 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombinant Enzyme for Cocaine Abuse - Drug Profile
Product Description
Mechanism Of Action
remimazolam besylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
RO-5256390 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SBP-0069330 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SJP-005 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Agonize MOR1 for Pain and Substance (Drug) Abuse - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Drug Abuse - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Substance Abuse and Drug Overdose - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Agonize CB1 and CB2 for CNS Diseases and Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit DAT for Substance Abuse - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Scavenge Free Radicals for Oxidative Stress Related Disorders - Drug Profile
Product Description
Mechanism Of Action
sodium oxybate IR - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptide to Inhibit ELK1 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptide to Target Kappa Opioid Receptors for Drug Addiction - Drug Profile
Product Description
Mechanism Of Action
tezampanel - Drug Profile
Product Description
Mechanism Of Action
History of Events
Titerquil-1055 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TNX-1300 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TRV-734 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Vaccine for Cocaine Addiction - Drug Profile
Product Description
Mechanism Of Action
History of Events
Vaccine for Drug Abuse - Drug Profile
Product Description
Mechanism Of Action
Vaccine for Methamphetamine Addiction - Drug Profile
Product Description
Mechanism Of Action
VVZN-3 - Drug Profile
Product Description
Mechanism Of Action
XHeII-053 - Drug Profile
Product Description
Mechanism Of Action
zolunicant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drug Addiction - Dormant Projects
Drug Addiction - Discontinued Products
Drug Addiction - Product Development Milestones
Featured News & Press Releases
Oct 04, 2021: InterveXion Therapeutics awarded federal grant to fund phase 2 study for methamphetamine use disorder
Jun 30, 2021: Embera NeuroTherapeutics announces first subject dosed in phase 2a study of EMB-001 in smoking cessation
Jun 24, 2021: Mydecine selects substance use disorder and smoking cessation for novel psychedelic molecule MYCO-004
May 07, 2021: KemPharm announces serdexmethylphenidate (SDX) has been classified as a schedule IV controlled substance by the DEA
Apr 19, 2021: InterveXion announces positive data in phase 2 study of IXT-m200 in participants with Methamphetamine use disorder
Feb 22, 2021: Entheon Biomedical announces ethics approval for in vivo DMT study
Jan 27, 2021: KemPharm receives FDA clearance to initiate KP879 clinical program for the treatment of stimulant use disorder
Dec 22, 2020: KemPharm files IND for KP879 for the treatment of Stimulant Use Disorder
Dec 09, 2020: Entheon Biomedical announces DMT drug supply agreement with Psygen Labs completion of initial DMT research drug batch and exercise of warrants
Dec 01, 2020: Entheon Biomedical announces CRO agreement with CHDR for phase 1 clinical trial; Centre for Human Drug Research led DMT study to start in 2021
Oct 05, 2020: InterveXion Therapeutics awarded federal grant to fund phase 2 study for Methamphetamine overdose
Aug 31, 2020: Embera NeuroTherapeutics announces first subject dosed in phase 2 study of EMB-001 in cocaine use disorder
Jan 30, 2020: Cerevel Therapeutics initiates phase 1 clinical trial of CVL-936, an investigational medicine in development to treat Substance Use Disorder
Dec 04, 2019: Intra-Cellular Therapies to present data on ITI-333 at the 58th annual meeting of the American College of Neuropsychopharmacology
Oct 07, 2019: BioCorRx announces capital restructuring and provides business update
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Drug Addiction, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Drug Addiction - Pipeline by Adjuvance Technologies Inc, 2022
Drug Addiction - Pipeline by Aelis Farma SAS, 2022
Drug Addiction - Pipeline by Aether Therapeutics Inc, 2022
Drug Addiction - Pipeline by Allaysis LLC, 2022
Drug Addiction - Pipeline by Amygdala Neurosciences Inc, 2022
Drug Addiction - Pipeline by Ananda Scientific Inc, 2022
Drug Addiction - Pipeline by Aphios Corp, 2022
Drug Addiction - Pipeline by Assertio Holdings Inc, 2022
Drug Addiction - Pipeline by Astraea Therapeutics LLC, 2022
Drug Addiction - Pipeline by Better Life Pharmaceuticals Inc, 2022
Drug Addiction - Pipeline by BioCorRx Inc, 2022
Drug Addiction - Pipeline by Camino Pharma LLC, 2022
Drug Addiction - Pipeline by Cerevel Therapeutics Holdings Inc, 2022
Drug Addiction - Pipeline by Charleston Laboratories Inc, 2022
Drug Addiction - Pipeline by Chiesi Farmaceutici SpA, 2022
Drug Addiction - Pipeline by Chiromics LLC, 2022
Drug Addiction - Pipeline by Clear Scientific LLC, 2022
Drug Addiction - Pipeline by Consegna Pharma Inc, 2022
Drug Addiction - Pipeline by Curemark LLC, 2022
Drug Addiction - Pipeline by D&A Pharma SAS, 2022
Drug Addiction - Pipeline by Daya Drug Discoveries Inc, 2022
Drug Addiction - Pipeline by DD Therapeutics LLC, 2022
Drug Addiction - Pipeline by Delix Therapeutics Inc, 2022
Drug Addiction - Pipeline by Denovo Biopharma LLC, 2022
Drug Addiction - Pipeline by Elysium Therapeutics Inc, 2022
Drug Addiction - Pipeline by Embera NeuroTherapeutics Inc, 2022
Drug Addiction - Pipeline by EncepHeal Therapeutics Inc, 2022
Drug Addiction - Pipeline by Ensysce Biosciences Inc, 2022
Drug Addiction - Pipeline by Entheon Biomedical Corp, 2022
Drug Addiction - Pipeline by EryDel SpA, 2022
Drug Addiction - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Drug Addiction - Pipeline by Foresee Pharmaceuticals Co Ltd, 2022
Drug Addiction - Pipeline by Hua Medicine Shanghai Ltd, 2022
Drug Addiction - Pipeline by IMV Inc, 2022
Drug Addiction - Pipeline by InterveXion Therapeutics LLC, 2022
Drug Addiction - Pipeline by Intra-Cellular Therapies Inc, 2022
Drug Addiction - Pipeline by Jazz Pharmaceuticals Plc, 2022
Drug Addiction - Pipeline by Kdac Therapeutics Inc, 2022
Drug Addiction - Pipeline by KemPharm Inc, 2022
Drug Addiction - Pipeline by Kinoxis Therapeutics Pty Ltd, 2022
Drug Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, 2022
Drug Addiction - Pipeline by MAKScientific LLC, 2022
Drug Addiction - Pipeline by MElkin Pharmaceuticals, 2022
Drug Addiction - Pipeline by Mind Medicine MindMed Inc, 2022
Drug Addiction - Pipeline by Mydecine Innovations Group Inc, 2022
Drug Addiction - Pipeline by Myosin Therapeutics Inc, 2022
Drug Addiction - Pipeline by Naprogenix Inc, 2022
Drug Addiction - Pipeline by NFL Biosciences SAS, 2022
Drug Addiction - Pipeline by Novartis AG, 2022
Drug Addiction - Pipeline by Omeros Corp, 2022
Drug Addiction - Pipeline by Ovid Therapeutics Inc, 2022
Drug Addiction - Pipeline by P2D Inc, 2022
Drug Addiction - Pipeline by PAION AG, 2022
Drug Addiction - Pipeline by Proniras Corp, 2022
Drug Addiction - Pipeline by Protagenic Therapeutics Inc, 2022
Drug Addiction - Pipeline by Qingdao Primedicine Pharmaceutical Technology Co Ltd, 2022
Drug Addiction - Pipeline by Relmada Therapeutics Inc, 2022
Drug Addiction - Pipeline by Revive Therapeutics Ltd, 2022
Drug Addiction - Pipeline by Saniona AB, 2022
Drug Addiction - Pipeline by Sen-Jam Pharmaceutical LLC, 2022
Drug Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022
Drug Addiction - Pipeline by Trevena Inc, 2022
Drug Addiction - Pipeline by Tris Pharma Inc, 2022
Drug Addiction - Pipeline by Vallon Pharmaceuticals Inc, 2022
Drug Addiction - Pipeline by Vivozon Inc, 2022
Drug Addiction - Pipeline by Zelira Therapeutics Ltd, 2022
Drug Addiction - Dormant Projects, 2022
Drug Addiction - Dormant Projects, 2022 (Contd..1)
Drug Addiction - Dormant Projects, 2022 (Contd..2)
Drug Addiction - Dormant Projects, 2022 (Contd..3)
Drug Addiction - Dormant Projects, 2022 (Contd..4)
Drug Addiction - Discontinued Products, 2022
List of Figures
Number of Products under Development for Drug Addiction, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
